Drugmakers Find a Salve That Nullifies Trump Tariffs
CEO of Pfizer Inc. Albert Bourla speaks in the Oval Office of the White House in Washington Sept. 30. Behind him, from left to right, are Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, President Donald Trump and Marty Makary, commissioner of the Food and Drug Administration.
Photographer: Francis Chung/Politico/BloombergHello, everyone, it’s Damian in New York. A White House crackdown on drug prices was, counterintuitively, warmly received by pharmaceutical investors. I’ll explain why, but first ...
President Donald Trump was pleased. Standing before a gaggle of reporters in the Oval Office on Tuesday, he explained that after years of twisting arms and cajoling pharmaceutical executives, he was finally lowering drug costs and “ending the era of global price gouging at the expense of American families.”